



A Pfizer Company

# SAFETY DATA SHEET

Revision date: 13-Sep-2016

Version: 3.3

Page 1 of 7

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Carboplatin Injection (Hospira, Inc..)

**Trade Name:** Not established

**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as Antineoplastic

### Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Hospira UK Limited  
Horizon  
Honey Lane  
Hurley  
Maidenhead, SL6 6RJ  
United Kingdom

**Emergency telephone number:**

**CHEMTREC (24 hours): 1-800-424-9300**

**Contact E-Mail:** pfizer-MSDS@pfizer.com

**Emergency telephone number:**

**International CHEMTREC (24 hours): +1-703-527-3887**

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Germ Cell Mutagenicity: Category 2

Reproductive Toxicity: Category 1B

### Label Elements

**Signal Word:** Danger

**Hazard Statements:**  
H360D - May damage the unborn child  
H341 - Suspected of causing genetic defects

**Precautionary Statements:**  
P201 - Obtain special instructions before use  
P202 - Do not handle until all safety precautions have been read and understood  
P281 - Use personal protective equipment as required  
P308 + P313 - IF exposed or concerned: Get medical attention/advice  
P405 - Store locked up  
P501 - Dispose of contents/container in accordance with all local and national regulations

## SAFETY DATA SHEET

Material Name: Carboplatin Injection (Hospira, Inc.)  
Revision date: 13-Sep-2016

Page 2 of 7  
Version: 3.3



### Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

### Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Carboplatin	41575-94-4	255-446-0	Acute Tox. 4 (H302) Repr. 1B (H360D) Muta. 2 (H341)	1

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*

#### Additional Information:

\* Proprietary  
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.  
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

- Eye Contact:** Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
- Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
- Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
- Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

## SAFETY DATA SHEET

Material Name: Carboplatin Injection (Hospira, Inc.)  
Revision date: 13-Sep-2016

Page 3 of 7  
Version: 3.3

**Medical Conditions** None known  
**Aggravated by Exposure:**

**Indication of the Immediate Medical Attention and Special Treatment Needed**  
**Notes to Physician:** None

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO<sub>2</sub>, extinguishing powder, foam, or water.

#### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Fine particles (such as dust and mists) may fuel fires/explosions.

#### Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

### 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

#### Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

#### Conditions for Safe Storage, Including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging.

**Specific end use(s):** Pharmaceutical product used as Antineoplastic

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Carboplatin

**Pfizer OEL TWA-8 Hr:** 60µg/m<sup>3</sup>  
**ACGIH Threshold Limit Value (TWA)** 0.002 mg/m<sup>3</sup>

#### Exposure Controls

## SAFETY DATA SHEET

Material Name: Carboplatin Injection (Hospira, Inc.)  
Revision date: 13-Sep-2016

Page 4 of 7  
Version: 3.3

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<b>Engineering Controls:</b>	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
<b>Personal Protective Equipment:</b>	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
<b>Hands:</b>	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
<b>Eyes:</b>	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
<b>Skin:</b>	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
<b>Respiratory protection:</b>	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Solution	<b>Color:</b>	Clear, colorless
<b>Odor:</b>	No data available.	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture
<b>Solvent Solubility:</b>	No data available		
<b>Water Solubility:</b>	No data available		
<b>pH:</b>	5-7		
<b>Melting/Freezing Point (°C):</b>	No data available		
<b>Boiling Point (°C):</b>	No data available.		
<b>Partition Coefficient: (Method, pH, Endpoint, Value)</b>			
<b>Water for Injection</b>			
No data available			
<b>Carboplatin</b>			
No data available			
<b>Decomposition Temperature (°C):</b>	No data available.		
<b>Evaporation Rate (Gram/s):</b>	No data available		
<b>Vapor Pressure (kPa):</b>	No data available		
<b>Vapor Density (g/ml):</b>	No data available		
<b>Relative Density:</b>	No data available		
<b>Viscosity:</b>	No data available		
<b>Flammability:</b>			
<b>Autoignition Temperature (Solid) (°C):</b>		No data available	
<b>Flammability (Solids):</b>		No data available	
<b>Flash Point (Liquid) (°C):</b>		No data available	
<b>Upper Explosive Limits (Liquid) (% by Vol.):</b>		No data available	
<b>Lower Explosive Limits (Liquid) (% by Vol.):</b>		No data available	

## SAFETY DATA SHEET

Material Name: Carboplatin Injection (Hospira, Inc.)  
Revision date: 13-Sep-2016

Page 5 of 7  
Version: 3.3

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available  
**Chemical Stability:** Stable under normal conditions of use.  
**Possibility of Hazardous Reactions**  
**Oxidizing Properties:** No data available  
**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.  
**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers  
**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

#### Information on Toxicological Effects

**General Information:** The information included in this section describes the potential hazards of the active ingredient  
**Short Term:** Harmful if swallowed (based on animal data) Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. In the workplace, platinum compounds have been reported to cause allergic skin and respiratory reactions.  
**Long Term:** Repeat-dose studies in animals have shown a potential to cause adverse effects on testes the developing fetus. May cause effects on blood and blood forming organs

#### Acute Toxicity: (Species, Route, End Point, Dose)

##### Carboplatin

Rat	Oral	LD 50	343 mg/kg
Rat	Para-periosteal	LD 50	72 mg/kg
Rat	Intraperitoneal	LD 50	118 mg/kg

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Carboplatin

26 Week(s)	Dog	Intravenous	140 mg/kg	LOAEL	Bone marrow
------------	-----	-------------	-----------	-------	-------------

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### Carboplatin

Embryo / Fetal Development	Rat	Oral	4 mg/kg/day	LOAEL	Fetotoxicity, Developmental toxicity
Embryo / Fetal Development	Rat	Oral	6 mg/kg/day	LOAEL	Fertility, Teratogenic

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Carboplatin

<i>In Vitro</i> Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Positive
<i>In Vivo</i> Mammalian Cell Mutagenicity	Hamster	Positive
<i>In Vivo</i> Micronucleus	Mouse	Positive

**Carcinogen Status:** Not listed as a carcinogen by IARC, NTP or US OSHA.

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

## SAFETY DATA SHEET

Material Name: Carboplatin Injection (Hospira, Inc.)  
Revision date: 13-Sep-2016

Page 6 of 7  
Version: 3.3

**Toxicity:** No data available  
**Persistence and Degradability:** No data available  
**Bio-accumulative Potential:** No data available  
**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### 15. REGULATORY INFORMATION

**Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture**

**Carboplatin**

<b>CERCLA/SARA 313 Emission reporting</b>	Not Listed
<b>California Proposition 65</b>	developmental toxicity 7/1/1990
<b>Standard for the Uniform Scheduling for Drugs and Poisons:</b>	Schedule 4
<b>EU EINECS/ELINCS List</b>	255-446-0

**Water for Injection**

<b>CERCLA/SARA 313 Emission reporting</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>Inventory - United States TSCA - Sect. 8(b)</b>	Present
<b>Australia (AICS):</b>	Present

## SAFETY DATA SHEET

Material Name: Carboplatin Injection (Hospira, Inc.)  
Revision date: 13-Sep-2016

Page 7 of 7  
Version: 3.3

### 15. REGULATORY INFORMATION

REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

### 16. OTHER INFORMATION

#### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed  
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child  
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects

**Data Sources:** Pfizer proprietary drug development information. Publicly available toxicity information.

**Reasons for Revision:** Updated Section 2 - Hazard Identification. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

**Revision date:** 13-Sep-2016  
Product Stewardship Hazard Communication

**Prepared by:** Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**